Argenx takes a step towards convenience

Last year Argenx bagged approval for the first FcRn antagonist, efgartigimod, trademarked as the intravenously delivered Vyvgart. Now a subcutaneous version is heading to regulators by year end, following success in the pivotal Adapt-SC trial in generalised myasthenia gravis.

There are some lingering questions about the incidence of adverse events with the subcutaneous formulation. But assuming that these will not worry the FDA, the big unknown at present is how Argenx will choose to price this more convenient option – something that, for now, it will not discuss.